ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
A Deep Representation Learning Method for Quantitative Immune Defense Function Evaluation and Its Clinical Applications.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The immune defense function protecting the body from invasive pathogens is a key indicator of an individual's health and lacks of methods for quantitative evaluation. This study introduces ImmuDef, a novel algorithm for precisely and quantitatively assessing anti-infection immune defense function based on RNA-seq data. ImmuDef selects immune signatures through comparisons of acquired immunodeficiency syndrome (AIDS) or severe sepsis vs. healthy controls (HC) and reduces dimension to construct a latent space via a variational autoencoder (VAE) model (QImmuDef-VAE), a representation deep learning model. Based on this model, a defense immune score (DImmuScore) was calculated by measuring the distance between a patient and HC within latent space. We validated ImmuDef on 3202 samples across four immune states: immunodeficiency, immunocompromised, immunocompetent, and immunoactive. As a result, DImmuScore achieves high classification accuracy (mean accuracy: 71.75%-76.25%) among samples with various immune states and infections. Furthermore, DImmuScore can serve as a metric for infectious disease severity, where its gradient directly quantifies disease severity. As an application, DImmuScore can be a strong prognostic indicator, effectively stratifying mortality/survival in both sepsis and COVID-19 patients with no symptomatic difference. This framework was validated across five infectious diseases, establishing the first quantitative standard for cross-disease immune defense assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.